Wikipedia

PITX2

Paired-like homeodomain transcription factor 2 also known as pituitary homeobox 2 is a protein that in humans is encoded by the PITX2 gene.[5][6][7]

PITX2
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesPITX2, ARP1, Brx1, IDG2, IGDS, IGDS2, IHG2, IRID2, Otlx2, PTX2, RGS, RIEG, RIEG1, RS, paired like homeodomain 2, ASGD4
External IDsOMIM: 601542; MGI: 109340; HomoloGene: 55454; GeneCards: PITX2; OMA:PITX2 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

5308

18741

Ensembl

ENSG00000164093

ENSMUSG00000028023

UniProt

Q99697

P97474

RefSeq (mRNA)

NM_001042502
NM_001042504
NM_001286942
NM_001287048
NM_011098

RefSeq (protein)

NP_001035967
NP_001035969
NP_001273871
NP_001273977
NP_035228

Location (UCSC)Chr 4: 110.62 – 110.64 MbChr 3: 128.99 – 129.01 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Function

edit

This gene encodes a member of the RIEG/PITX homeobox family, which is in the bicoid class of homeodomain proteins. This protein acts as a transcription factor[8] and regulates procollagen lysyl hydroxylase gene expression. This protein is involved in the development of the eye, tooth, and abdominal organs. This protein acts as a transcriptional regulator involved in the basal and hormone-regulated activity of prolactin. A similar protein in other vertebrates is involved in the determination of left-right asymmetry during development. Three transcript variants encoding distinct isoforms have been identified for this gene.[7]

Pitx2 is responsible for the establishment of the left-right axis, the asymmetrical development of the heart, lungs, and spleen, twisting of the gut and stomach, as well as the development of the eyes. Once activated Pitx2 will be locally expressed in the left lateral mesoderm, tubular heart, and early gut which leads to the asymmetrical development of organs and looping of the gut. When Pitx2 is deleted, the irregular morphogenesis of organs results on the left hand side. Pitx2 is left-laterally expressed controlling the morphology of the left visceral organs. Expression of Pitx2 is controlled by an intronic enhancer ASE and Nodal. It appears that while Nodal controls cranial expression of Pitx2, ASE controls left – right expression of Pitx2, which leads to the asymmetrical development of the left sided visceral organs, such as the spleen and liver. Collectively, Pitx2 first acts to prevent the apoptosis of the extraocular muscles followed by acting as the myogenic programmer of the extraocular muscle cells.[9][10][11] There have also been studies showing different isoforms of the transcription factor: Pitx2a, Pitx2b, and Pitx2c, each with distinct and non-overlapping functions.[12]

Studies have shown that in chick embryos, Pitx2 is a direct regulator of cVg1, a growth factor homologous to mammalian GDF1. cVg1 is a Transforming growth factor beta signal that is expressed posteriorly before the formation of the embryo germ layers.[13] The Pitx2 regulation of cVg1 is essential both during normal embryonic development and during establishment of polarity in twins created by experimental division of a single, original embryo. Pitx2 is shown to be essential for upregulation of cVg1 through the binding of enhancers, and is necessary for the proper expression of cVg1 in the posterior marginal zone. Expression of cVg1 in the PMZ is in turn necessary for the proper development of the primitive streak. Experimental knockouts of the PITX2 gene are associated with the subsequent upregulation of related Pitx1, which is able to partially compensate for the loss of Pitx2. Pitx2's ability to regulate the polarity of the embryo may be responsible for the ability of developing chicks to establish proper polarity in embryos created by cuts performed as late as the blastoderm stage.[14]

Pitx2 plays a role in limb myogenesis. Pitx2 can determine the development and activation of the MyoD gene (the gene responsible for skeletal myogenesis). Studies have shown that expression of Pitx2 happens before MyoD is expressed in muscles. Further studies show that Pitx2 is directly recruited to act on the MyoD core enhancer and thus, directing the expression of the MyoD gene. Pitx 2 is in a parallel pathway with Myf5 and Myf6, as both paths effect expression of MyoD. However, in the absence of the parallel pathway, Pitx2 can continue activating MyoD genes. The expression of Pitx2 saves MyoD gene expression and keeps expressing this gene for limb myogenesis. Yet, the Pitx 2 pathway is PAX3 dependent and requires this gene to enact limb myogenesis. Studies support this finding as in the absence of PAX3, there is Pitx2 expression deficit and thus, MyoD does not express itself in limb myogenesis. The Pitx2 gene is thus shown to be downstream of Pax3 and serve as an intermediate between Pax3 and MyoD. In conclusion, Pitx2 plays an integral role in limb myogenesis.[15]

Pitx2 isoforms are expressed in a sexually dimorphic manner during rat gonadal development.[16]

Pitx2 expression has been shown to be important for normal anterior pituitary gland development. Studies using mice embryos established Pitx2 expression is required in a dosage dependent manner. Mice with a homozygous null mutation of the Pitx2 gene showed that it is not required for initial pituitary formation but is needed for further development. Littermates of normal homozygotes, Pitx2+/+, versus homozygous null, Pitx2-/-, at embryonic day 10.5 provided a comparison of differing pouch sizes and cell types. Mice with the homozygous null gene had a smaller pouch and mesenchymal cell growth and differentiation arrested. While embryos with a hypomorphic mutation, Pitx2neo/+, of the gene were considered morphologically normal.[17] Along with normal pituitary expansion, Pitx2 is needed for normal expression of cell transcription genes of hormones produced in the anterior pituitary. Of which are luteinizing hormone (LH), follicle stimulating hormone (FSH), gonadotropin-releasing hormone (GnRH), growth hormone (GH), and thyroid stimulating hormone (TSH). A study conducted using Pitx2neo/neo mice at postnatal day 1, found the transcripts of hormone genes for LH beta (LHb) and FSH beta (FSHb), and GnRH receptor (GnRHR) were nearly absent or nearly abolished, respectively. While transcription genes for GH and TSH producing cells, and growth hormone releasing hormone receptor (GHRHR) of Pitx2neo homozygous mice were moderately reduced. Further analysis of the transcription factors, Gata2, Egr1 and SF1, involved in LHb and FSHb differentiation found a reduction or absence of them in Pitx2neo/neo mice. The transcription factors, Prop1 and Pit1, which control development of GH and TSH producing cells, were also studied in Pitx2neo homozygous mice but only Pit1 expression was reduced. A reduction or absence of the transcription factors of the gonadotropin cells of the anterior pituitary leads to a loss of full pituitary cell function. [18]

Clinical significance

edit

Mutations in this gene are associated with Axenfeld-Rieger syndrome (ARS), iridogoniodysgenesis syndrome (IGDS), and sporadic cases of Peters anomaly. This protein plays a role in the terminal differentiation of somatotroph and lactotroph cell phenotypes.[7]

Pitx2 is overexpressed in many cancers. For example, thyroid,[19] ovarian,[20] and colon cancer[21] all have higher levels of Pitx2 compared to noncancerous tissues. Scientists speculate that cancer cells improperly turn on Pitx2, leading to uncontrolled cell proliferation. This is consistent with the role of Pitx2 in regulating the growth-regulating genes cyclin D2,[22] cyclin D1,[23] and C-Myc.[23]

In renal cancer, Pitx2 regulates expression of ABCB1, a multidrug transporter, by binding to the promoter region of ABCB1.[24] Increased expression of Pitx2 in renal cancer cells is associated with increased expression of ABCB1.[24] Thus, renal cancer cells that overexpress ABCB1 have a greater resistance to chemotherapeutic agents.[24] In experiments where Pitx2 expression was decreased, renal cancer cells had decreased cell proliferation and greater susceptibility to doxorubicin treatment, which is consistent with other results.[24]

In human esophageal squamous cell carcinoma (ESCC), Pitx2 is overexpressed compared to normal esophageal squamous cells.[25] In addition, greater expression of Pitx2 is positively correlated with clinical aggressiveness of ESCC.[25] Also, ESCC patients with high Pitx2 expression did not respond as well to definitive chemoradiotherapy (CRT) compared to ESCC patients with low Pitx2 expression.[25] Thus, physicians may be able to use Pitx2 expression to predict how ESCC patients will respond to cancer treatment.[25]

In Congenital Heart Disease, heterozygous mutations in Pitx2 have been involved in the development of Tetralogy of Fallot, ventricular septal defects, atrial septal defects, transposition of great arteries, and endocardial cushion defect (ECD).[26][27][28] The mutations of the Pitx2 gene are created through alternative splicing. The isoform of Pitx2 important for cardiogenesis is Pitx2c. The lack of expression of this particular isoform correlates with these congenital defects. Pitx2 mutations significantly reduce transcriptional activity of Pitx2 and synergistic activation between Pitx2 and NKX2(also important for development of the heart).[26] The large phenotypic spectrum due to the mutation of Pitx2 may be attributed to a variety of factors including: different genetic backgrounds, epigenetic modifiers and delayed/complete penetrance.[27] The mutation of Pitx2 is not defined as the cause of these congenital heart defects, but currently perceived as a risk factor for their development.[28]

Studies have also shown that Pitx2 displays an oncogenic role that is correlated with patients that have lung adenocarcinoma (LUAD). Pitx2 was overexpressed in LUAD when compared with neighboring normal tissues and is reported to increase clinical stages of the carcinoma and decrease survival. Patients with LUAD that presented with higher levels of Pitx2 had a lower overall survival rate compared to those with lower levels of Pitx2. The Pitx2 gene plays a role in lung adenocarcinoma that is dependent on activating the Wnt/β-catenin signaling pathway. When analyzing experimental findings from this Wnt/β-catenin signaling pathway, a TCGA dataset showed that Pitx2 had a positive correlation with WNT3A. These results propose that Pixt2 is directly bound to the WNT3A promoter region which will enhance WNT3A's transcription. This transcriptional regulation of WNT3A has been reported to encourage migration and the infiltration process of LUAD which can worsen a LUAD patients’ prognosis. Experimental knockdown of Pixt2 repressed tumor growth of LUAD; this supports the claim that Pixt2 is associated with the tumorigenesis of cancers, specifically in lung adenocarcinoma. These results suggest that Pitx2 may have a potential to serve as a biomarker for patients that present with LUAD.

References

edit
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000164093 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000028023 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Arakawa H, Nakamura T, Zhadanov AB, Fidanza V, Yano T, Bullrich F, et al. (April 1998). "Identification and characterization of the ARP1 gene, a target for the human acute leukemia ALL1 gene". Proceedings of the National Academy of Sciences of the United States of America. 95 (8): 4573–4578. Bibcode:1998PNAS...95.4573A. doi:10.1073/pnas.95.8.4573. PMC 22531. PMID 9539779.
  6. ^ Héon E, Sheth BP, Kalenak JW, Sunden SL, Streb LM, Taylor CM, et al. (August 1995). "Linkage of autosomal dominant iris hypoplasia to the region of the Rieger syndrome locus (4q25)". Human Molecular Genetics. 4 (8): 1435–1439. doi:10.1093/hmg/4.8.1435. PMID 7581385.
  7. ^ a b c "Entrez Gene: PITX2 paired-like homeodomain transcription factor 2".
  8. ^ Logan M, Pagán-Westphal SM, Smith DM, Paganessi L, Tabin CJ (August 1998). "The transcription factor Pitx2 mediates situs-specific morphogenesis in response to left-right asymmetric signals". Cell. 94 (3): 307–317. doi:10.1016/S0092-8674(00)81474-9. PMID 9708733. S2CID 14375165.
  9. ^ Campione M, Steinbeisser H, Schweickert A, Deissler K, van Bebber F, Lowe LA, et al. (March 1999). "The homeobox gene Pitx2: mediator of asymmetric left-right signaling in vertebrate heart and gut looping". Development. 126 (6): 1225–1234. doi:10.1242/dev.126.6.1225. PMID 10021341.
  10. ^ Shiratori H, Yashiro K, Shen MM, Hamada H (August 2006). "Conserved regulation and role of Pitx2 in situs-specific morphogenesis of visceral organs". Development. 133 (15): 3015–3025. doi:10.1242/dev.02470. PMID 16835440.
  11. ^ Zacharias AL, Lewandoski M, Rudnicki MA, Gage PJ (January 2011). "Pitx2 is an upstream activator of extraocular myogenesis and survival". Developmental Biology. 349 (2): 395–405. doi:10.1016/j.ydbio.2010.10.028. PMC 3019256. PMID 21035439.
  12. ^ Essner JJ, Branford WW, Zhang J, Yost HJ (March 2000). "Mesendoderm and left-right brain, heart and gut development are differentially regulated by pitx2 isoforms". Development. 127 (5): 1081–1093. doi:10.1242/dev.127.5.1081. PMID 10662647.
  13. ^ Weeks DL, Melton DA (December 1987). "A maternal mRNA localized to the vegetal hemisphere in Xenopus eggs codes for a growth factor related to TGF-beta". Cell. 51 (5): 861–867. doi:10.1016/0092-8674(87)90109-7. PMID 3479264. S2CID 40022353.
  14. ^ Torlopp A, Khan MA, Oliveira NM, Lekk I, Soto-Jiménez LM, Sosinsky A, et al. (December 2014). "The transcription factor Pitx2 positions the embryonic axis and regulates twinning". eLife. 3: e03743. doi:10.7554/eLife.03743. PMC 4371885. PMID 25496870.
  15. ^ L'honoré A, Ouimette JF, Lavertu-Jolin M, Drouin J (November 2010). "Pitx2 defines alternate pathways acting through MyoD during limb and somitic myogenesis". Development. 137 (22): 3847–3856. doi:10.1242/dev.053421. PMID 20978076.
  16. ^ Nandi SS, Ghosh P, Roy SS (2011). "Expression of PITX2 homeodomain transcription factor during rat gonadal development in a sexually dimorphic manner". Cellular Physiology and Biochemistry. 27 (2): 159–170. doi:10.1159/000325218. PMID 21325833.
  17. ^ Gage PJ, Suh H, Camper SA (October 1999). "Dosage requirement of Pitx2 for development of multiple organs". Development. 126 (20): 4643–4651. doi:10.1242/dev.126.20.4643. PMID 10498698.
  18. ^ Suh H, Gage PJ, Drouin J, Camper SA (January 2002). "Pitx2 is required at multiple stages of pituitary organogenesis: pituitary primordium formation and cell specification". Development. 129 (2): 329–337. doi:10.1242/dev.129.2.329. PMID 11807026.
  19. ^ Huang Y, Guigon CJ, Fan J, Cheng SY, Zhu GZ (April 2010). "Pituitary homeobox 2 (PITX2) promotes thyroid carcinogenesis by activation of cyclin D2". Cell Cycle. 9 (7): 1333–1341. doi:10.4161/cc.9.7.11126. PMID 20372070.
  20. ^ Fung FK, Chan DW, Liu VW, Leung TH, Cheung AN, Ngan HY (2012). "Increased expression of PITX2 transcription factor contributes to ovarian cancer progression". PLOS ONE. 7 (5): e37076. Bibcode:2012PLoSO...737076F. doi:10.1371/journal.pone.0037076. PMC 3352869. PMID 22615897.
  21. ^ Hirose H, Ishii H, Mimori K, Tanaka F, Takemasa I, Mizushima T, et al. (October 2011). "The significance of PITX2 overexpression in human colorectal cancer". Annals of Surgical Oncology. 18 (10): 3005–3012. doi:10.1245/s10434-011-1653-z. PMID 21479692. S2CID 25710972.
  22. ^ Kioussi C, Briata P, Baek SH, Rose DW, Hamblet NS, Herman T, et al. (November 2002). "Identification of a Wnt/Dvl/beta-Catenin --> Pitx2 pathway mediating cell-type-specific proliferation during development". Cell. 111 (5): 673–685. doi:10.1016/s0092-8674(02)01084-x. PMID 12464179. S2CID 16108479.
  23. ^ a b Baek SH, Kioussi C, Briata P, Wang D, Nguyen HD, Ohgi KA, et al. (March 2003). "Regulated subset of G1 growth-control genes in response to derepression by the Wnt pathway". Proceedings of the National Academy of Sciences of the United States of America. 100 (6): 3245–3250. Bibcode:2003PNAS..100.3245B. doi:10.1073/pnas.0330217100. PMC 152277. PMID 12629224.
  24. ^ a b c d Lee WK, Chakraborty PK, Thévenod F (August 2013). "Pituitary homeobox 2 (PITX2) protects renal cancer cell lines against doxorubicin toxicity by transcriptional activation of the multidrug transporter ABCB1". International Journal of Cancer. 133 (3): 556–567. doi:10.1002/ijc.28060. PMID 23354914. S2CID 39427967.
  25. ^ a b c d Zhang JX, Tong ZT, Yang L, Wang F, Chai HP, Zhang F, et al. (June 2013). "PITX2: a promising predictive biomarker of patients' prognosis and chemoradioresistance in esophageal squamous cell carcinoma". International Journal of Cancer. 132 (11): 2567–2577. doi:10.1002/ijc.27930. PMID 23132660. S2CID 44870191.
  26. ^ a b Sun YM, Wang J, Qiu XB, Yuan F, Xu YJ, Li RG, et al. (February 2016). "PITX2 loss-of-function mutation contributes to tetralogy of Fallot". Gene. 577 (2): 258–264. doi:10.1016/j.gene.2015.12.001. PMID 26657035.
  27. ^ a b Zhao CM, Peng LY, Li L, Liu XY, Wang J, Zhang XL, et al. (April 20, 2015). "PITX2 Loss-of-Function Mutation Contributes to Congenital Endocardial Cushion Defect and Axenfeld-Rieger Syndrome". PLOS ONE. 10 (4): e0124409. Bibcode:2015PLoSO..1024409Z. doi:10.1371/journal.pone.0124409. PMC 4404345. PMID 25893250.
  28. ^ a b Wei D, Gong XH, Qiu G, Wang J, Yang YQ (May 2014). "Novel PITX2c loss-of-function mutations associated with complex congenital heart disease". International Journal of Molecular Medicine. 33 (5): 1201–1208. doi:10.3892/ijmm.2014.1689. PMID 24604414.

Further reading

edit
edit

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

Retrieved from "https://en.wiki.x.io/w/index.php?title=PITX2&oldid=1235797830"